Does perioperative systemic therapy represent the optimal therapeutic paradigm in organ-confined, muscle-invasive urothelial carcinoma?
作者信息
Scafuri Luca, Sciarra Antonella, Crocetto Felice, Ferro Matteo, Buonerba Carlo, Ugliano Francesco, Guerra Germano, Sanseverino Roberto, Lorenzo Giuseppe Di
机构信息
Oncology Unit, Hospital 'Andrea Tortora,' ASL Salerno, Pagani, 84016, Italy.
Associazione O.R.A., Somma Vesuviana, Naples, Italy.
出版信息
Future Sci OA. 2021 Oct 28;7(9):FSO770. doi: 10.2144/fsoa-2021-0092. eCollection 2021 Oct.
Abstract
摘要
相似文献
1
Does perioperative systemic therapy represent the optimal therapeutic paradigm in organ-confined, muscle-invasive urothelial carcinoma?围手术期全身治疗是局限性、肌层浸润性尿路上皮癌的最佳治疗模式吗？
Future Sci OA. 2021 Oct 28;7(9):FSO770. doi: 10.2144/fsoa-2021-0092. eCollection 2021 Oct.
2
Urothelial carcinoma of the bladder and the upper tract: disparate twins.膀胱和上尿路尿路上皮癌：迥异的双生子。
J Urol. 2013 Apr;189(4):1214-21. doi: 10.1016/j.juro.2012.05.079. Epub 2012 Sep 27.
3
Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.对于具有变异组织学类型的肌层浸润性膀胱癌，在根治性膀胱切除术之前进行新辅助化疗。
Cancer. 2017 Nov 15;123(22):4346-4355. doi: 10.1002/cncr.30907. Epub 2017 Jul 25.
4
Perioperative Systemic Treatment for Muscle-Invasive Bladder Cancer: Current Evidence and Future Perspectives.肌层浸润性膀胱癌的围手术期全身治疗：当前证据与未来展望。
Int J Mol Sci. 2021 Jul 4;22(13):7201. doi: 10.3390/ijms22137201.
5
Urothelial carcinoma in situ response to cisplatin-based neoadjuvant chemotherapy, or lack thereof: Impact on patient selection for organ preservation in muscle-invasive disease?尿路上皮癌原位对顺铂为基础的新辅助化疗的反应，或缺乏反应：对肌层浸润性疾病行器官保留患者选择的影响？
Urol Oncol. 2020 Nov;38(11):850.e1-850.e7. doi: 10.1016/j.urolonc.2020.06.014. Epub 2020 Jul 18.
6
Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer.肌肉浸润性膀胱癌的新辅助化疗和辅助化疗
Eur Urol. 2009 Feb;55(2):348-58. doi: 10.1016/j.eururo.2008.10.016. Epub 2008 Oct 16.
7
Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma.肌层浸润性膀胱癌和上尿路尿路上皮癌患者化疗与手术的最佳时机
Urol Clin North Am. 2018 May;45(2):155-167. doi: 10.1016/j.ucl.2017.12.002. Epub 2018 Feb 21.
8
Improving the outcome of patients with muscle invasive urothelial carcinoma of the bladder with neoadjuvant gemcitabine/cisplatin chemotherapy: A single institution experience.采用吉西他滨/顺铂新辅助化疗改善肌层浸润性膀胱尿路上皮癌患者的预后：单机构经验
Can Urol Assoc J. 2014 Mar;8(3-4):e287-93. doi: 10.5489/cuaj.1643.
9
Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer.膀胱癌的化疗：新辅助化疗、膀胱保留、辅助化疗及转移性癌的治疗指南
Urology. 2007 Jan;69(1 Suppl):62-79. doi: 10.1016/j.urology.2006.10.041.
10
Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma.肌层浸润性膀胱癌和上尿路尿路上皮癌的围手术期免疫治疗
Urol Clin North Am. 2018 May;45(2):287-295. doi: 10.1016/j.ucl.2017.12.011.
引用本文的文献
1
Effect of Clinical Complete Remission Following Neoadjuvant Pembrolizumab or Chemotherapy in Bladder-Preservation Strategy in Patients with Muscle-Invasive Bladder Cancer Declining Definitive Local Therapy.新辅助派姆单抗或化疗后临床完全缓解对拒绝确定性局部治疗的肌层浸润性膀胱癌患者膀胱保留策略的影响。
Cancers (Basel). 2024 Feb 23;16(5):894. doi: 10.3390/cancers16050894.
2
Comparison of trimodality therapy and neoadjuvant chemotherapy combined with radical cystectomy for the survival of muscle-invasive bladder cancer: a population-based analysis.三联疗法与新辅助化疗联合根治性膀胱切除术治疗肌层浸润性膀胱癌的生存比较：基于人群的分析。
Eur J Med Res. 2023 Oct 11;28(1):422. doi: 10.1186/s40001-023-01408-9.
3
Immune Checkpoint Inhibitors as a Neoadjuvant/Adjuvant Treatment of Muscle-Invasive Bladder Cancer: A Systematic Review.免疫检查点抑制剂作为肌肉浸润性膀胱癌的新辅助/辅助治疗：一项系统评价
Cancers (Basel). 2022 May 21;14(10):2545. doi: 10.3390/cancers14102545.
4
Novel Therapeutic Opportunities in Neoadjuvant Setting in Urothelial Cancers: A New Horizon Opened by Molecular Classification and Immune Checkpoint Inhibitors.在尿路上皮癌的新辅助治疗环境中出现的新治疗机会：分子分类和免疫检查点抑制剂开辟的新前景。
Int J Mol Sci. 2022 Jan 20;23(3):1133. doi: 10.3390/ijms23031133.
本文引用的文献
1
Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy.中性粒细胞与白蛋白比值可预测接受新辅助化疗后行根治性膀胱切除术的膀胱癌患者的死亡率。
Future Sci OA. 2021 Apr 20;7(7):FSO709. doi: 10.2144/fsoa-2021-0008. eCollection 2021 Aug.
2
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.纳武利尤单抗辅助治疗与安慰剂用于肌肉浸润性尿路上皮癌。
N Engl J Med. 2021 Jun 3;384(22):2102-2114. doi: 10.1056/NEJMoa2034442.
3
Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis.接受根治性膀胱切除术的局限性肌层浸润性膀胱癌新辅助化疗三个周期与四个周期的比较：一项回顾性多机构分析
Front Oncol. 2021 May 11;11:651745. doi: 10.3389/fonc.2021.651745. eCollection 2021.
4
Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303.肌层浸润性膀胱癌的围手术期帕博利珠单抗治疗：III 期 KEYNOTE-866 和 KEYNOTE-905/EV-303 研究。
Future Oncol. 2021 Aug;17(24):3137-3150. doi: 10.2217/fon-2021-0273. Epub 2021 May 19.
5
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.阿替利珠单抗辅助治疗与观察用于肌层浸润性尿路上皮癌（IMvigor010）：一项多中心、开放标签、随机、III 期临床试验。
Lancet Oncol. 2021 Apr;22(4):525-537. doi: 10.1016/S1470-2045(21)00004-8. Epub 2021 Mar 12.
6
Impact of Adjuvant Chemotherapy on Survival of Patients with Advanced Residual Disease at Radical Cystectomy following Neoadjuvant Chemotherapy: Systematic Review and Meta-Analysis.新辅助化疗后辅助化疗对根治性膀胱切除术后晚期残留疾病患者生存的影响：系统评价和荟萃分析
J Clin Med. 2021 Feb 8;10(4):651. doi: 10.3390/jcm10040651.
7
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
8
Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.新辅助化疗对比单纯根治性膀胱切除术改善肌层浸润性膀胱癌患者总生存的荟萃分析。
BMC Urol. 2020 Oct 14;20(1):158. doi: 10.1186/s12894-020-00733-z.
9
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.阿维鲁单抗维持治疗晚期或转移性尿路上皮癌。
N Engl J Med. 2020 Sep 24;383(13):1218-1230. doi: 10.1056/NEJMoa2002788. Epub 2020 Sep 18.
10
Laparoscopic radical cystectomy with extracorporeal urinary diversion: an Italian single-center experience with 10-year outcomes.腹腔镜根治性膀胱切除术联合体外尿流改道术：意大利单中心10年随访结果
Minerva Urol Nefrol. 2020 Oct;72(5):641-643. doi: 10.23736/S0393-2249.20.03850-3. Epub 2020 Jun 16.
Zotero 插件